NCT02061722View on ClinicalTrials.gov

[PETDE10] Imaging of PDE10A Enzyme Levels in Huntington's Disease Gene Expansion Carriers and Healthy Controls With PET.

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Huntington's Disease
Interventions
RADIATION

PET Imaging with [18F]MNI-659

"The radioligands \[11C\]raclopride and \[18F\]MNI-659 will be administered at doses less than 10 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.~The injected radioactivity of \[11C\]raclopride will be 300 MBq/70 kg of body weight ± 10%.~The injected radioactivity of \[18F\]MNI-659 will be 185 MBq/70 kg of body weight ± 10%."

Trial Locations (8)

Unknown

The Memory Clinic, Rigshopitalet, Copenhagen

K5Q112

Leiden University Medical Center, Department of Neurology, Leiden

0372 Oslo

University of Oslo, Nevrologisk poliklinikk, Oslo

SE-221 85

Skane Universitetssjukhus Lund, Neurologiska kliniken, Lund

SE-141 86

Karolinska Universitetssjukhus, Huddinge, Stockholm

SE-171 76

Karolinska University Hospital, Stockholm

KTA Karolinska Trial Alliance, Stockholm

SE-751 85

Neurologkliniken Akademiska sjukhuset, ing 85, Uppsala

All Listed Sponsors
lead

CHDI Foundation, Inc.

OTHER

NCT02061722 - [PETDE10] Imaging of PDE10A Enzyme Levels in Huntington's Disease Gene Expansion Carriers and Healthy Controls With PET. | Biotech Hunter | Biotech Hunter